Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease

α-Synuclein in Lewy bodies

Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · see citing works

Loss of autophagy in the central nervous system causes neurodegeneration in mice

Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J.-I., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E., et al. (2006) · Nature · doi:10.1038/nature04723 · Cited by 3,500 · see citing works

The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease

Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310 · see citing works

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135 · see citing works

Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.

Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124 · see citing works

Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy

Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · see citing works

Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease

Kriks, S., Shim, J., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo‐Reid, L., Auyeung, G., Antonacci, C. L., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,912 · see citing works

Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells

Lister, R., Pelizzola, M., Kida, Y. S., Hawkins, R. D., Nery, J. R., Hon, G. C., Antosiewicz‐Bourget, J., O’Malley, R. C., Castanon, R., Klugman, S. A., et al. (2011) · Nature · doi:10.1038/nature09798 · Cited by 1,545 · see citing works

Induced pluripotent stem cell technology: a decade of progress.

Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525 · see citing works

α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models

Cooper, A. A., Gitler, A. D., Cashikar, A. G., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., et al. (2006) · Science · doi:10.1126/science.1129462 · Cited by 1,377 · see citing works

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341 · see citing works

Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208 · see citing works

A three-dimensional human neural cell culture model of Alzheimer’s disease

Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195 · see citing works

Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities

Menzies, F. M., Fleming, A., Caricasole, A., Bento, C. F., Andrews, S. P., Ashkenazi, A., Füllgrabe, J., Jackson, A., Jimenez Sanchez, M., Karabiyik, C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.022 · Cited by 1,134 · see citing works

A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci

Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112 · see citing works

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases

Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. (2016) · eLife · doi:10.7554/elife.12813 · Cited by 990 · see citing works

Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons

Jo, J., Xiao, Y., Sun, A. X., Cukuroglu, E., Tran, H.-D., Göke, J., Tan, Z. Y., Saw, T. Y., Tan, C.-P., Lokman, H., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.07.005 · Cited by 861 · see citing works

α-Synuclein impairs macroautophagy: implications for Parkinson’s disease

Winslow, A. R., Chen, C.-W., Corrochano, S., Acevedo-Arozena, A., Gordon, D. E., Peden, A. A., Lichtenberg, M., Menzies, F. M., Ravikumar, B., Imarisio, S., et al. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201003122 · Cited by 825 · see citing works

Human iPSC-based modeling of late-onset disease via progerin-induced aging

Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777 · see citing works

Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715 · see citing works

Dopamine-modified α-synuclein blocks chaperone-mediated autophagy

Martínez‐Vicente, M., Tallóczy, Z., Kaushik, S., Massey, A. C., Mazzulli, J. R., Mosharov, E. V., Hodara, R., Fredenburg, R. A., Wu, D.-C., Follenzi, A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32806 · Cited by 633 · see citing works

Interplay of LRRK2 with chaperone-mediated autophagy

Orenstein, S. J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L. S., Dauer, W., Consiglio, A., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3350 · Cited by 588 · see citing works

Phenotype, diagnosis, and treatment of Gaucher's disease.

Grabowski, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61522-6 · Cited by 582 · see citing works

Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease

Sànchez-Dànes, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jiménez-Delgado, S., Caig, C., Mora, S., Guglielmo, C. D., Ezquerra, M., Patel, B., Giralt, A., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200215 · Cited by 576 · see citing works

Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains

Gegg, M. E., Burke, D., Heales, S., Cooper, J., Hardy, J., Wood, N., & Schapira, A. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 551 · see citing works

Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains

Alvarez‐Erviti, L., Rodríguez-Oroz, M. C., Cooper, J. A. D., Caballero, C., Ferrer, I., Obeso, J. A., & Schapira, A. H. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.198 · Cited by 550 · see citing works

LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase

Reczek, D., Schwake, M., Schröder, J., Hughes, H., Blanz, J., Jin, X., Brondyk, W. H., Patten, S. V., Edmunds, T., & Säftig, P. (2007) · Cell · doi:10.1016/j.cell.2007.10.018 · Cited by 544 · see citing works

Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells

Plowey, E., Cherra, S. J., Liu, Y.-J., & Chu, C. T. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05217.x · Cited by 523 · see citing works

iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis

Schöndorf, D. C., Aureli, M., McAllister, F., Hindley, C., Mayer, F., Schmid, B., Sardi, S., Valsecchi, M., Hoffmann, S., Schwarz, L. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms5028 · Cited by 516 · see citing works

Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease

Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003985 · Cited by 508 · see citing works

Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease

Sawkar, A. R., Cheng, W., Beutler, E., Wong, C., Balch, W. E., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192582899 · Cited by 508 · see citing works

Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression

Soldner, F., Stelzer, Y., Shivalila, C., Abraham, B. J., Latourelle, J. C., Barrasa, M. I., Goldmann, J. E., Myers, R. H., Young, R. A., & Jaenisch, R. (2016) · Nature · doi:10.1038/nature17939 · Cited by 496 · see citing works

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease

Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475 · see citing works

Neuropathology provides clues to the pathophysiology of Gaucher disease

Wong, K., Sidransky, E., Verma, A. M., Mixon, T., Sandberg, G. D., Wakefield, L. K., Morrison, A. L., Lwin, A., Colegial, C. H., Allman, J. M., et al. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.04.011 · Cited by 453 · see citing works

Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance

Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448 · see citing works

Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease

Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433 · see citing works

Isogenic Human iPSC Parkinson’s Model Shows Nitrosative Stress-Induced Dysfunction in MEF2-PGC1α Transcription

Ryan, S. D., Dolatabadi, N., Chan, S. F., Zhang, X., Akhtar, M. W., Parker, J., Soldner, F., Sunico, C. R., Nagar, S., Talantova, M. V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.009 · Cited by 430 · see citing works

Therapeutic goals in the treatment of Gaucher disease.

Pastores, G., Weinreb, N., Aerts, H., Andria, G., Cox, T., Giralt, M., Grabowski, G., Mistry, P., & Tylki-Szymańska, A. (2004) · Seminars in hematology (Print) · doi:10.1053/j.seminhematol.2004.07.009 · Cited by 410 · see citing works

Occurrence of Parkinson's syndrome in type 1 Gaucher disease

Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401 · see citing works

Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations

Alcalay, R. N., Levy, O. A., Waters, C., Fahn, S., Ford, B., Kuo, S., Mazzoni, P., Pauciulo, M. W., Nichols, W. C., Gan‐Or, Z., et al. (2015) · Brain · doi:10.1093/brain/awv179 · Cited by 388 · see citing works

α-Synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models

Mazzulli, J. R., Zunke, F., Ole Isacson, A., Studer, L., & Krainc, D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520335113 · Cited by 382 · see citing works

Parkinsonism among Gaucher disease carriers

Göker-Alpan, Ö., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A. M., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366 · see citing works

Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling

Mekhoubad, S., Bock, C., de Boer, A. S., Kiskinis, E., Meissner, A., & Eggan, K. C. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.02.014 · Cited by 362 · see citing works

Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases

Mu, T., Ong, D. S. T., Wang, Y., Balch, W. E., Yates, J. R., Segatori, L., & Kelly, J. W. (2008) · Cell · doi:10.1016/j.cell.2008.06.037 · Cited by 359 · see citing works

Abberant α-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy

Xilouri, M., Vogiatzi, T., Vekrellis, K., Park, D. S., & Stefanis, L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005515 · Cited by 353 · see citing works

ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons

Fernandes, H. J. R., Hartfield, E. M., Christian, H., Emmanoulidou, E., Zheng, Y. H., Booth, H., Bogetofte, H., Lang, C., Ryan, B. J., Sardi, S. P., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.01.013 · Cited by 352 · see citing works

Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells

Cao, K., Graziotto, J. J., Blair, C. D., Mazzulli, J. R., Erdos, M. R., Krainc, D., & Collins, F. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002346 · Cited by 350 · see citing works

ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity

Ron, I., & Horowitz, M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi240 · Cited by 331 · see citing works

Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease

Osellame, L. D., Rahim, A. A., Hargreaves, I. P., Gegg, M. E., Richard-Loendt, A., Brandner, S., Waddington, S. N., Schapira, A. H. V., & Duchen, M. R. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.014 · Cited by 329 · see citing works

Parkinson's disease–associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes

Wang, W., Wang, X., Fujioka, H., Hoppel, C. L., Whone, A. L., Caldwell, M. A., Cullen, P. J., Liu, J., & Zhu, X. (2015) · Nature Medicine · doi:10.1038/nm.3983 · Cited by 324 · see citing works

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

McNeill, A., Magalhães, J., Shen, C.-G., Chau, K., Hughes, D., Mehta, A., Foltynie, T., Cooper, J., Abramov, A., Gegg, M. E., et al. (2014) · Brain : a journal of neurology · doi:10.1093/brain/awu020 · Cited by 315 · see citing works

Disrupted Autophagy Leads to Dopaminergic Axon and Dendrite Degeneration and Promotes Presynaptic Accumulation of α-Synuclein and LRRK2 in the Brain

Friedman, L. G., Lachenmayer, M. L., Wang, J., He, L., Poulose, S. M., Komatsu, M., Holstein, G. R., & Yue, Z. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5809-11.2012 · Cited by 303 · see citing works

Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration

Davis, M. Y., Trinh, K., Thomas, R. E., Yu, S., Germanos, A. A., Whitley, B. N., Sardi, S. P., Montine, T. J., & Pallanck, L. J. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005944 · Cited by 294 · see citing works

Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity

Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P., & Krainc, D. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5575-11.2012 · Cited by 291 · see citing works

Activation of -Glucocerebrosidase Reduces Pathological -Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons

Mazzulli, J. R., Zunke, F., Tsunemi, T., Toker, N., Jeon, S., Burbulla, L. F., Patnaik, S., Sidransky, E., Marugán, J., Sue, C. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0628-16.2016 · Cited by 275 · see citing works

VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function

Tang, F., Liu, W., Hu, J.-X., Erion, J., Ye, J., Mei, L., & Xiong, W. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.001 · Cited by 274 · see citing works

VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for  -Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease

Tang, F.-L., Erion, J. R., Tian, Y., Liu, W., Yin, D.-M., Ye, J., Tang, B., Mei, L., & Xiong, W.-C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0042-15.2015 · Cited by 269 · see citing works

Autophagy and A lpha‐ S ynuclein: R elevance to P arkinson's D isease and R elated S ynucleopathies

Xilouri, M., Brekk, O. R., & Stefanis, L. (2016) · Movement Disorders · doi:10.1002/mds.26477 · Cited by 266 · see citing works

Mutant A53T α-Synuclein Induces Neuronal Death by Increasing Mitochondrial Autophagy

Choubey, V., Safiulina, D., Vaarmann, A., Cagalinec, M., Warȩski, P., Kuum, M., Zharkovsky, A., & Kaasik, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.132514 · Cited by 261 · see citing works

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies

Sardi, S. P., Clarke, J. L., Viel, C., Chan, M., Tamsett, T. J., Treleaven, C. M., Bu, J., Sweet, L., Passini, M. A., Dodge, J. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220464110 · Cited by 252 · see citing works

Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease

Clark, L. N., Ross, B., Wang, Y., Mejia‐Santana, H., Harris, J. M., Louis, E. D., Cote, L. J., Andrews, H., Fahn, S., Waters, C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000276989.17578.02 · Cited by 252 · see citing works

The relationship between glucocerebrosidase mutations and Parkinson disease

Migdalska‐Richards, A., & Schapira, A. H. V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13385 · Cited by 235 · see citing works

Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease

Magalhães, J., Gegg, M. E., Migdalska‐Richards, A., Doherty, M. K., Whitfield, P. D., & Schapira, A. H. V. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw185 · Cited by 234 · see citing works

Glucocerebrosidase mutations are an important risk factor for Lewy body disorders

Göker-Alpan, Ö., Giasson, B. I., Eblan, M. J., Nguyen, J., Hurtig, H. I., Lee, V. M.-Y., Trojanowski, J. Q., & Sidransky, E. (2006) · Neurology · doi:10.1212/01.wnl.0000230215.41296.18 · Cited by 229 · see citing works

A New Glucocerebrosidase Chaperone Reduces -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism

Aflaki, E., Borger, D. K., Moaven, N., Stubblefield, B. K., Rogers, S. A., Patnaik, S., Schoenen, F. J., Westbroek, W., Zheng, W., Sullivan, P., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0636-16.2016 · Cited by 228 · see citing works

Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide

Zunke, F., Moise, A. C., Belur, N. R., Gelyana, E., Stojkovska, I., Dzaferbegovic, H., Toker, N., Jeon, S., Fredriksen, K., & Mazzulli, J. R. (2017) · Neuron · doi:10.1016/j.neuron.2017.12.012 · Cited by 222 · see citing works

Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation

Su, Y.-C., & Qi, X. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt301 · Cited by 221 · see citing works

iPSC-Derived Dopamine Neurons Reveal Differences between Monozygotic Twins Discordant for Parkinson’s Disease

Woodard, C. M., Campos, B. A., Kuo, S., Nirenberg, M. J., Nestor, M. W., Zimmer, M., Mosharov, E. V., Sulzer, D. L., Zhou, H., Paull, D. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.023 · Cited by 220 · see citing works

The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms

Steet, R., Chung, S., Wustman, B. A., Powe, A. C., Do, H., & Kornfeld, S. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605928103 · Cited by 219 · see citing works

Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis

Joksimovic, M., Yun, B. A., Kittappa, R., Anderegg, A. M., Chang, W. W., Taketo, M. M., McKay, R. D. G., & Awatramani, R. B. (2009) · Nature Neuroscience · doi:10.1038/nn.2243 · Cited by 213 · see citing works

Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study

Narita, A., Shirai, K., Itamura, S., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.292 · Cited by 207 · see citing works

Autophagy and Its Normal and Pathogenic States in the Brain

Yamamoto, A., & Yue, Z. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014149 · Cited by 204 · see citing works

Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models

Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616152114 · Cited by 203 · see citing works

Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation

Chung, S. Y., Kishinevsky, S., Mazzulli, J. R., Graziotto, J. J., Mrejeru, A., Mosharov, E. V., Puspita, L., Valiulahi, P., Sulzer, D. L., Milner, T. A., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.012 · Cited by 201 · see citing works

Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage

Cleeter, M. W. J., Chau, K., Gluck, C. A., Mehta, A. B., Hughes, D. A., Duchen, M. R., Wood, N. W., Hardy, J., Cooper, J. A. D., & Schapira, A. H. V. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.10.010 · Cited by 201 · see citing works

Gaucher Disease and Parkinsonism: A Phenotypic and Genotypic Characterization

Tayebi, N., Callahan, M., Madike, V., Stubblefield, B. K., Orviský, E., Krasnewich, D. M., Fillano, J. J., & Sidransky, E. (2001) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3201 · Cited by 200 · see citing works

Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease

Pandey, M. K., Burrow, T. A., Rani, R., Martin, L. J., Witte, D. P., Setchell, K. D. R., McKay, M. A., Magnusen, A. F., Zhang, W., Liou, B., et al. (2017) · Nature · doi:10.1038/nature21368 · Cited by 193 · see citing works

A53T Human α-Synuclein Overexpression in Transgenic Mice Induces Pervasive Mitochondria Macroautophagy Defects Preceding Dopamine Neuron Degeneration

Chen, L., Xie, Z., Turkson, S., & Zhuang, X. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0089-14.2015 · Cited by 185 · see citing works

LRRK2 at the interface of autophagosomes, endosomes and lysosomes

Roosen, D. A., & Cookson, M. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0140-1 · Cited by 185 · see citing works

Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders

Göker-Alpan, Ö., Stubblefield, B. K., Giasson, B. I., & Sidransky, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0741-7 · Cited by 179 · see citing works

GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers

Kim, S., Yun, S. P., Lee, S., Umanah, G. K. E., Bandaru, V. V. R., Yin, X., Rhee, P., Karuppagounder, S. S., Kwon, S., Lee, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700465115 · Cited by 179 · see citing works

Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation

Li, W., Lesuisse, C., Xu, Y., Troncoso, J. C., Price, D. L., & Lee, M. K. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1370-04.2004 · Cited by 178 · see citing works

Gaucher disease: new molecular approaches to diagnosis and treatment

Beutler, E. (1992) · Science · doi:10.1126/science.1589760 · Cited by 178 · see citing works

Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein

Bae, E.-J., Yang, N.-Y., Song, M., Lee, C.-S., Lee, J. S., Jung, B. C., Lee, H.-J., Kim, S., Masliah, E., Sardi, S. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms5755 · Cited by 178 · see citing works

Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism

Manning-Bog, A., Schüle, B., & Langston, J. W. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.06.009 · Cited by 176 · see citing works

Lysosomal storage and impaired autophagy lead to inflammasome activation in G aucher macrophages

Aflaki, E., Moaven, N., Borger, D. K., Lopez, G. J., Westbroek, W., Chae, J. J., Marugán, J., Patnaik, S., Maniwang, E., Gonzalez, A. N., et al. (2015) · Aging Cell · doi:10.1111/acel.12409 · Cited by 161 · see citing works

ADrosophilaModel of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin

Kinghorn, K. J., Grönke, S., Castillo-Quan, J. I., Woodling, N. S., Li, L., Sirka, E., Gegg, M. E., Mills, K. A., Hardy, J., Bjedov, I., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4527-15.2016 · Cited by 157 · see citing works

The Pharmacological Chaperone Isofagomine Increases Activity of the Gaucher Disease L444P Mutant Form of β-Glucosidase

Khanna, R., Benjamin, E. R., Pellegrino, L. J., Schilling, A., Rigat, B., Soska, R., Nafar, H., Ranes, B., Feng, J., Yi, L., et al. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07588.x · Cited by 155 · see citing works

Integrative genomic and functional analyses reveal neuronal subtype differentiation bias in human embryonic stem cell lines

Wu, H., Xu, J., Pang, Z., Ge, W.-H., Kim, K. J., Blanchi, B., Chen, C.-F., Südhof, T., & Sun, Y. (2007) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0706199104 · Cited by 153 · see citing works

Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration

Farfel‐Becker, T., Vitner, E. B., Kelly, S. L., Bame, J. R., Duan, J., Shinder, V., Merrill, A. H., Dobrenis, K., & Futerman, A. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt468 · Cited by 153 · see citing works

Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase

Bendikov-Bar, I., Maor, G., Filocamo, M., et al. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.10.007 · Cited by 147 · see citing works

Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy

Ahmed, I., Liang, Y., Schools, S., Dawson, V. L., Dawson, T. M., & Savitt, J. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0209-12.2012 · Cited by 144 · see citing works

Exploring the link between glucocerebrosidase mutations and parkinsonism

Westbroek, W., Gustafson, A. M., & Sidransky, E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.003 · Cited by 144 · see citing works

Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice

Rocha, E. M., Smith, G. A., Park, E. Y. H., Cao, H., Graham, A.-R., Brown, E., McLean, J. R., Hayes, M. A., Beagan, J. A., Izen, S. C., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6307 · Cited by 144 · see citing works

The role of saposin C in Gaucher disease

Tamargo, R. J., Velayati, A., Goldin, E., & Sidransky, E. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.04.024 · Cited by 139 · see citing works

Gaucher Disease: Clinical, Biological and Therapeutic Aspects

Dandana, A., Khelifa, S. B., Chahed, H., et al. (2015) · Pathobiology · doi:10.1159/000440865 · Cited by 137 · see citing works

Aberrant epigenome in iPSC‐derived dopaminergic neurons from Parkinson's disease patients

Fernández‐Santiago, R., Carballo‐Carbajal, I., Castellano, G., Torrent, R., Richaud, Y., Sánchez‐Danés, A., Vilarrasa‐Blasi, R., Sánchez‐Pla, Á., Mosquera, J. L., Soriano, J., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505439 · Cited by 136 · see citing works

Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.

Zimran, A., Altarescu, G., & Elstein, D. (2013) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2012.09.006 · Cited by 136 · see citing works

Increased incidence of Parkinson disease among relatives of patients with Gaucher disease

Halperin, A., Elstein, D., & Zimran, A. (2006) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2006.02.004 · Cited by 133 · see citing works

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits

Sun, Y., Liou, B., Ran, H., Skelton, M. R., Williams, M. T., Vorhees, C. V., Kitatani, K., Hannun, Y. A., Witte, D. P., Xu, Y.-H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp580 · Cited by 133 · see citing works

Discovery, Structure–Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase

Patnaik, S., Zheng, W., Choi, J. H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300063b · Cited by 130 · see citing works

LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance

Rothaug, M., Zunke, F., Mazzulli, J. R., Schweizer, M., Altmeppen, H. C., Lüllmann‐Rauch, R., Kallemeijn, W. W., Gaspar, P., Aerts, J. M. F. G., Glatzel, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405700111 · Cited by 122 · see citing works

Gaucher disease: insights from a rare Mendelian disorder.

Sidransky, E. (2012) · PubMed · Cited by 121 · see citing works

Pathogenic effects of novel mutations in the P‐type ATPase ATP13A2 ( PARK9 ) causing Kufor‐Rakeb syndrome, a form of early‐onset parkinsonism

Park, J., Mehta, P. M., Cooper, A. A., Veivers, D., Heimbach, A., Stiller, B., Kubisch, C., Fung, V. S. C., Krainc, D., Mackay‐Sim, A., et al. (2011) · Human Mutation · doi:10.1002/humu.21527 · Cited by 119 · see citing works

Enzyme replacement and substrate reduction therapy for Gaucher disease

Shemesh, E., Deroma, L., Bembi, B., Deegan, P. B., Hollak, C. E. M., Weinreb, N. J., & Cox, T. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010324.pub2 · Cited by 119 · see citing works

Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs

Aflaki, E., Stubblefield, B. K., Maniwang, E., Lopez, G., Moaven, N., Goldin, E., Marugan, J., Patnaik, S., Dutra, A., Southall, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008659 · Cited by 114 · see citing works

A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy

Richter, F., Fleming, S. M., Watson, M. B., Lemesre, V., Pellegrino, L. J., Ranes, B. E., Zhu, C., Mortazavi, F., Mulligan, C. K., Sioshansi, P. C., et al. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0294-x · Cited by 109 · see citing works

Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity

Berg-Fussman, A., Grace, M., Ioannou, Y. A., et al. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82412-7 · Cited by 109 · see citing works

Two phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, β-glucocerebrosidase

Jović, M., Kean, M. J., Szentpétery, Z., et al. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-06-0553 · Cited by 104 · see citing works

Chemical Chaperones and Permissive Temperatures Alter the Cellular Localization of Gaucher Disease Associated Glucocerebrosidase Variants

Sawkar, A. R., Schmitz, M., Zimmer, K., Reczek, D., Edmunds, T., Balch, W. E., & Kelly, J. W. (2006) · ACS Chemical Biology · doi:10.1021/cb600187q · Cited by 102 · see citing works

Gaucher Disease and Its Treatment Options

Bennett, L. L., & Mohan, D. (2013) · The Annals of Pharmacotherapy · doi:10.1177/1060028013500469 · Cited by 97 · see citing works

Association Between Progranulin and Gaucher Disease

Jian, J., Zhao, S., Tian, Q., Liu, H., Zhao, Y., Chen, W., Grünig, G., Torres, P., Wang, B. C., Zeng, B. J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.004 · Cited by 90 · see citing works

Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice

Xu, Y., Xu, K., Sun, Y., Liou, B., Quinn, B., Li, R.-H., Xue, L., Zhang, W., Setchell, K. D. R., Witte, D. P., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu105 · Cited by 89 · see citing works

Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones

Yang, C., Rahimpour, S., Lu, J., Pacák, K., Ikejiri, B. L., Brady, R. O., & Zhuang, Z. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221046110 · Cited by 75 · see citing works

ERdj3 Is an Endoplasmic Reticulum Degradation Factor for Mutant Glucocerebrosidase Variants Linked to Gaucher’s Disease

Tan, Y. L., Genereux, J. C., Pankow, S., Aerts, J. M. F. G., Yates, J. R., & Kelly, J. W. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.06.008 · Cited by 74 · see citing works

Defective Autophagy in Parkinson’s Disease: Lessons from Genetics

Zhang, H., Duan, C., & Yang, H. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8787-5 · Cited by 72 · see citing works

Parkinson's disease: acid‐glucocerebrosidase activity and alpha‐synuclein clearance

Blanz, J., & Säftig, P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13517 · Cited by 70 · see citing works

High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase

Goldin, E., Zheng, W., Motabar, O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029861 · Cited by 69 · see citing works

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse

Sun, Y., Ran, H., Liou, B., Quinn, B., Zamzow, M., Zhang, W., Bielawski, J., Kitatani, K., Setchell, K. D. R., Hannun, Y. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019037 · Cited by 64 · see citing works

Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2

Zunke, F., Andresen, L., Wesseler, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514005113 · Cited by 62 · see citing works

Advances in GBA-associated Parkinson's disease – Pathology, presentation and therapies

Barkhuizen, M., Anderson, D. G., & Grobler, A. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.12.004 · Cited by 58 · see citing works

Acid β-Glucosidase: Intrinsic Fluorescence and Conformational Changes Induced by Phospholipids and Saposin C

Qi, X., & Grabowski, G. A. (1998) · Biochemistry · doi:10.1021/bi980785+ · Cited by 57 · see citing works

Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease

Jung, O., Patnaik, S., Marugán, J., Sidransky, E., & Westbroek, W. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1174583 · Cited by 57 · see citing works

Gaucher disease paradigm: From ERAD to comorbidity

Bendikov-Bar, I., & Horowitz, M. (2012) · Human Mutation · doi:10.1002/humu.22124 · Cited by 56 · see citing works

Glucocerebrosidase deficits in sporadic Parkinson disease

Murphy, K. E., & Halliday, G. M. (2014) · Autophagy · doi:10.4161/auto.29074 · Cited by 53 · see citing works

Genetic causes of Parkinson's disease and their links to autophagy regulation

Pan, P., & Yue, Z. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70037-3 · Cited by 52 · see citing works

Human acid β-glucosidase: Glycosylation is required for catalytic activity

Grace, M., & Grabowski, G. A. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)92388-g · Cited by 46 · see citing works

Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones

Yang, C., Swallows, C. L., Zhang, C., Lu, J., Xiao, H., Brady, R. O., & Zhuang, Z. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321341111 · Cited by 45 · see citing works

Mannose 6‐phosphate‐independent Lysosomal Sorting of LIMP ‐2

Blanz, J., Zunke, F., Markmann, S., et al. (2015) · Traffic · doi:10.1111/tra.12313 · Cited by 38 · see citing works

Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice

Liou, B., Peng, Y., Li, R., Inskeep, V., Zhang, W., Quinn, B., Dasgupta, N., Blackwood, R., Setchell, K. D. R., Fleming, S. M., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw322 · Cited by 35 · see citing works

Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation

Yang, C., Wang, H., Zhu, D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424288112 · Cited by 27 · see citing works

Gaucher-Associated Parkinsonism

Li, Y., Li, P., Liang, H., Zhao, Z., Hashimoto, M., & Wei, J. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0176-8 · Cited by 26 · see citing works

Immunoelectron microscopic localization of mannose-terminal glucocerebrosidase in lysosomes of rat liver Kupffer cells.

Murray, G. J., & Jin, F. S. (1995) · Journal of Histochemistry & Cytochemistry · doi:10.1177/43.2.7822772 · Cited by 23 · see citing works

Development of targeted therapies for Parkinson's disease and related synucleinopathies

Sybertz, E. J., & Krainc, D. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r047381 · Cited by 18 · see citing works

An Immunoelectron Microscopic Study of Glucocerebrosidase in Type 1 Gaucher's Disease Spleen

Willemsen, R., van Dongen, J. J. M., Aerts, J. M. F. G., et al. (1988) · Ultrastructural Pathology · doi:10.3109/01913128809032232 · Cited by 18 · see citing works

Comparison of the ability of phospholipids from rat liver lysosomes to reconstitute glucocerebrosidase

Basu, A., Glew, R. H., Wherrett, J. R., et al. (1986) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(86)90238-9 · Cited by 13 · see citing works

Ageing, Cellular Senescence and Neurodegenerative Disease

Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448 · see citing works

When friendship turns sour: Effective communication between mitochondria and intracellular organelles in parkinson’s disease

Lin, T.-K., Lin, K.-J., Lin, K.-L., Liou, C.-W., Chen, S.-D., Chuang, Y.-C., Wang, P.-W., Chuang, J.-H., & Wang, T.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607392 · Cited by 19 · see citing works